COO · Cooper Companies, Inc.
$76.17
-0.43 (-0.56%)
At close · Aug 14
Market Cap
$14.86B
Shares
195.03M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$4.09B
+5.1%
FY2025
Net Income
$374.9M
-4.4%
FY2025
Gross Margin
65.54%
-1.1pp
FY2025
Operating Margin
16.69%
-1.4pp
FY2025
Diluted EPS
$1.87
-4.6%
FY2025
Operating Cash Flow
$796.1M
+12.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $4.3B – $4.34B | $4.23B | $4.09B | $3.9BG | $3.59B | $3.31B | $2.92B | $2.43B | $2.65B | $2.53B | $2.14B | $1.97B | $1.8B | $1.72B | $1.59B | $1.45B | $1.33B | $1.16B | $1.08B | $1.05B | |
| — | $1.46B | $1.41B | $1.3B | $1.24B | $1.17B | $966.7M | $896.1M | $896.6M | $900.5M | $773.2M | $793.7M | $726.8M | $626.21M | $560.92M | $521.13M | $526.03M | $481.79M | $483.93M | $437.35M | |
| — | $2.77B | $2.68B | $2.6B | $2.36B | $2.14B | $1.96B | $1.53B | $1.76B | $1.63B | $1.37B | $1.17B | $1.07B | $1.09B | $1.03B | $924.01M | $804.8M | $676.72M | $596.49M | $610.03M | |
| — | — | 65.54% | 66.64% | 65.62% | 64.67% | 66.92% | 63.14% | 66.21% | 64.45% | 63.85% | 59.65% | 59.56% | 63.55% | 64.67% | 63.94% | 60.47% | 58.41% | 55.21% | 58.24% | |
| — | $172.8M | $172.2M | $155.1M | $137.4M | $110.3M | $92.7M | $93.3M | $86.7M | $84.8M | $69.2M | $65.4M | $69.6M | $66.26M | $58.83M | $51.73M | $43.58M | $35.27M | $33.3M | $35.47M | |
| — | $1.91B | $1.63B | $1.53B | $1.5B | $1.34B | $1.21B | $992.5M | $996.2M | $973.3M | $799.1M | $722.8M | $712.5M | $683.12M | $610.74M | $564.9M | $513.14M | $433.06M | $391.59M | $429.3M | |
| — | $195.4M | $199.2M | $201.2M | $186.2M | $179.5M | $146.1M | $137.2M | $145.8M | $146.7M | $68.4M | $60.8M | $51.5M | $35.71M | $30.24M | $23.98M | $20.53M | $18.06M | $17.86M | $16.77M | |
| — | — | $377.4M | $375.1M | $367.7M | $346.1M | $309.3M | — | $280.8M | $275.1M | $188.4M | $198.3M | $191.4M | $138.2M | $125.35M | $111.21M | $98.15M | $94M | $92.6M | $82.19M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $0 | $0 | $424K | $3.89M | $1.52M | |
| — | $497.9M | $682.9M | $705.7M | $533.1M | $507.6M | $505.8M | $311.8M | $546.7M | $403.1M | $429.1M | $324.1M | $236.7M | $306.49M | $305.95M | $283.4M | $227.56M | $189.91M | $149.86M | $126.96M | |
| — | — | 16.69% | 18.12% | 14.84% | 15.34% | 17.31% | 12.83% | 20.6% | 15.92% | 20.06% | 16.48% | 13.17% | 17.84% | 19.27% | 19.61% | 17.1% | 16.39% | 13.87% | 12.12% | |
| — | — | $1.06B | $1.08B | $900.8M | $853.7M | $815.1M | — | $827.5M | $678.2M | $617.5M | $522.4M | $428.1M | $444.69M | $431.29M | $394.61M | $325.71M | $283.91M | $242.46M | $209.15M | |
| — | $93.1M | $100M | $114.3M | $105.3M | $57.3M | $23.1M | $36.8M | $68M | $82.7M | $33.4M | $26.2M | $18.1M | $7.97M | $9.17M | $11.77M | $17.34M | $36.67M | $44.14M | $53.03M | |
| — | $7.7M | -$16.4M | -$9.1M | -$14.9M | $25M | $8.8M | -$8.5M | -$1.3M | $11.5M | -$1.7M | -$2.3M | -$3.1M | -$1.99M | $1.41M | $229K | -$963K | -$1.07M | $7.29M | $28K | |
| — | $412.5M | $566.5M | $582.3M | $412.9M | $475.3M | $491.5M | $266.5M | $477.4M | $331.9M | $394M | $295.6M | $215.5M | $296.53M | $312.27M | $275.45M | $192.76M | $124.43M | $114.83M | $73.96M | |
| — | $176.7M | $191.6M | $190M | $118.7M | $89.5M | -$2.45B | $28.1M | $10.7M | $192M | $21.1M | $20.7M | $10.4M | $24.71M | $15.37M | $26.81M | $17.33M | $11.62M | $14.28M | $10.01M | |
| — | $235.8M | $374.9M | $392.3M | $294.2M | $385.8M | $2.94B | $238.4M | $466.7M | $139.9M | $372.9M | $273.9M | $203.5M | $269.86M | $296.15M | $248.34M | $175.43M | $112.8M | $100.55M | $63.96M | |
| — | — | 9.16% | 10.07% | 8.19% | 11.66% | 100.76% | 9.81% | 17.59% | 5.52% | 17.43% | 13.93% | 11.32% | 15.71% | 18.65% | 17.18% | 13.18% | 9.74% | 9.31% | 6.11% | |
| — | — | — | — | — | — | — | — | — | $0 | $0 | $1M | $1.6M | $1.97M | $755K | $305K | $0 | $0 | — | — | |
| — | — | — | — | — | $385.8M | $2.94B | $238.4M | $466.7M | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | $3.08B | $213.5M | $450.3M | $89.3M | $487.2M | -$24M | $119.2M | $180.68M | $313.12M | $235.21M | $174.65M | $108.39M | $112.87M | — | |
| USD/shares | — | — | $1.88 | $1.97 | $1.49 | $1.95 | $14.95 | $1.21 | $2.36 | $0.71 | $1.91 | $1.41 | $1.05 | $1.40 | $1.52 | $1.30 | $0.94 | $0.62 | $0.56 | $0.36 |
| USD/shares | $4.45 – $4.60* | — | $1.87 | $1.96G | $1.48 | $1.94 | $14.79 | $1.20 | $2.33 | $0.70 | $1.88 | $1.40 | $1.04 | $1.38 | $1.49 | $1.26 | $0.91 | $0.61 | $0.55 | $0.36 |
| shares | — | — | 199.1M | 198.9M | 197.9M | 197.4M | 196.8M | 196.4M | 197.6M | 196.4M | 195.6M | 194M | 194M | 192.24M | 194.46M | 191.65M | 187.62M | 182.12M | 180.69M | 179.98M |
| shares | — | — | 200M | 200.4M | 199.3M | 198.8M | 199.2M | 198.4M | 200M | 198.8M | 198.4M | 196M | 196.8M | 195.84M | 198.74M | 196.61M | 193.24M | 186.02M | 181.91M | 180.47M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2008–FY2025: $1.03B in buybacks, $46.22M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
4.06×
Peer median 3.28×
EV/EBIT
34.50×
Peer median 31.00×
P/E (TTM)
65.10×
Peer median 31.59×
Peer medians compare against the 24 similar-size Medical Instruments & Supplies companies (of 48 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Coopervision Segment | $2,743,800,000 | $2,609,400,000 | $2,423,700,000 | $2,243,300,000 | $2,152,000,000 | $1,843,000,000 | $1,972,900,000 | $1,882,000,000 |
| Coopersurgical Segment | $1,348,600,000 | $1,286,000,000 | $1,169,500,000 | $1,065,100,000 | $770,500,000 | $587,900,000 | $680,500,000 | $650,800,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $2,054,000,000 | $1,965,900,000 | $1,812,200,000 | $1,638,500,000 | $1,339,200,000 | $1,103,600,000 | $1,211,800,000 | $1,162,200,000 |
| Europe | $1,253,200,000 | $1,155,900,000 | $1,041,200,000 | $987,200,000 | $957,900,000 | $789,800,000 | $854,800,000 | $846,500,000 |
| Rest of the World | $785,200,000 | $773,600,000 | $739,800,000 | $682,700,000 | $625,400,000 | $537,500,000 | $586,800,000 | $524,100,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Sphere Other | $1,392,500,000 | $1,352,200,000 | $1,289,300,000 | $1,241,500,000 | — | — | — | — |
| Toric and Multifocal | $1,351,300,000 | $1,257,200,000 | $1,134,400,000 | $1,001,800,000 | — | — | — | — |
| Office and Surgical | $824,000,000 | $774,700,000 | $689,500,000 | $633,600,000 | — | — | — | — |
| Fertility | $524,600,000 | $511,300,000 | $960,000,000 | $863,000,000 | $638,400,000 | $229,100,000 | $258,100,000 | $250,400,000 |
| Multifocal Lens | — | — | $305,700,000 | $528,800,000 | — | $197,000,000 | $202,900,000 | $196,600,000 |
| Non Single Use Sphere and Other | — | — | $583,900,000 | $1,159,800,000 | — | $518,800,000 | $581,800,000 | $573,900,000 |
| Office and Surgical Products | — | — | $689,500,000 | $1,267,200,000 | $902,600,000 | $358,800,000 | $422,400,000 | $400,400,000 |
| Single Use Sphere Lens | — | — | $705,400,000 | $1,323,200,000 | — | $529,000,000 | $568,200,000 | $520,100,000 |
| Toric Lens | — | — | $828,700,000 | $1,474,800,000 | $1,395,000,000 | $598,200,000 | $620,000,000 | $591,400,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cooper Vision Segment | $729,600,000 | $676,200,000 | $587,700,000 | $494,300,000 | $481,300,000 | $375,700,000 | $506,400,000 | $479,800,000 |
| Cooper Surgical Segment | $43,400,000 | $118,300,000 | $16,100,000 | $67,100,000 | $71,800,000 | -$14,700,000 | $87,900,000 | -$19,900,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Coopervision Segment | 26.6% | 25.9% | 24.2% | 22% | 22.4% | 20.4% | 25.7% | 25.5% |
| Coopersurgical Segment | 3.2% | 9.2% | 1.4% | 6.3% | 9.3% | -2.5% | 12.9% | -3.1% |
Key facts
CIK
711404
CUSIP
216648501
13F (30d)
640 filings
612 filers
Visit website
Investor relations